Abbott Pays $400 Million Upfront For Reata’s Preclinical AIM Programs

Adding on to the two companies’ collaboration around chronic kidney disease candidate bardoxolone, Abbott will pay a record upfront for preclinical assets to co-develop and co-commercialize Reata’s antioxidant inflammation modulators in a variety of disease areas.